Author: Mark Campbell

Why Decentralisation Is The Future Of Clinical Trials

Posted

Decentralisation of clinical trials has been a growing topic of discussion and development over the last few years, enabled further by the advancement of available technologies. Here, we explore what we mean when we talk about decentralised trials and discuss why the clinical research industry has been reluctant to pursue this route. We illuminate the […]

Clinical Trials: To Decentralise, Or Not To Decentralise?

Posted

We explore how to look beyond the most common challenges faced by study organisers, and identify whether a clinical trial is an appropriate candidate for either a fully decentralised or hybrid model.

Clinical Trial Continuity During The Ongoing COVID-19 Pandemic

Posted

The clinical trial landscape has changed dramatically since the outbreak of COVID-19. For the clinical research industry, these past few months have been anything but business as usual. However, it hasn’t meant clinical trials can’t continue, and many in the industry have been working together to find a ‘new normal’.

Incorporating Home Visits In Clinical Trials

Posted

When it’s not feasible for patients to visit study sites due to travel restrictions, alternatives such as home health services must be considered.